We partner with researchers, the life sciences industry, investors, research institutions and other funders to accelerate the discovery and development of new treatments, tools and diagnostics.
By working with us, you can access our full support along the translational pathway, including our therapeutic discovery and clinical infrastructure and expertise in drug and technology development.
Cancer Research Horizons is our translational arm. It works closely with researchers, industry partners and investors to translate cutting-edge innovations into new tools, treatments and diagnostics for people affected by cancer.
Our Centre for Drug Development partners with biotechs, pharmaceutical companies and academics worldwide to deliver early-phase clinical trials, accelerating the next generation of cancer treatments to patients.
Our network of adult and paediatric experimental cancer medicine centres across the UK provides a unique service for early phase trials. It supports trials from industry and other funders, in addition to treatments we develop and optimise ourselves.
C-Further is an international consortium started by Cancer Research Horizons and LifeArc. It’s bringing together researchers, clinicians, drug discovery and development scientists, industry partners, and investors with a shared commitment to creating new cancer therapeutics for children and young people.
We offer dedicated funding and support to accelerate the translation of research into novel cancer therapeutics and technologies.
Cancer Research Horizons offers entrepreneurial training programmes for researchers looking to turn their innovations into real-world impact. These programmes can show you how to build a business, connect you to a network of like-minded people and help you find the right advice and support when you need it.
Explore entrepreneurial training opportunities
The Drug Development Project, managed by our Centre for Drug Development, can support you with the clinical development of promising new cancer treatments.
Learn about the Drug Development Project
Cancer Research Horizons’ Translation Fund can help kick-start your project or bridge a gap to get your project to the next stage. Proposals should have a clearly defined endpoint that is achievable in the short to medium term.
Learn about the Translation Fund
Our Therapeutic Catalyst and Childhood Cancer Therapeutic Catalyst awards offer funding and support if you have a novel insight into cancer biology that can be targeted therapeutically to treat cancer.
Learn about the Therapeutic Catalyst
Learn about the Childhood Cancer Therapeutic Catalyst
The Data Catalyst, offered through Cancer Research Horizons, can support you with funding for cleaning, annotation, curation, linking or storage of data that has significant commercial potential.
Cancer Research Horizons’ Seed Fund aims to bridge the gap between cutting-edge science and patient impact. It can support you with investment if you have an early-stage opportunity that holds promise for real innovation, worldwide, from within and beyond the Cancer Research UK network.
C-Further can support you if you have a therapeutic project related to childhood cancers, with a well-validated target or existing therapeutic modality. Projects are run collaboratively, leveraging the consortium’s drug discovery expertise and resources to advance projects closer to patients.
Learn how to access support through the consortium
Our Therapeutic Innovation team at Cancer Research Horizons work with researchers and industry to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines. The team can support you with expertise across the full early-stage pipeline—from target identification to lead optimisation and candidate selection for preclinical and regulatory development.
Learn how you can work with Therapeutic Innovation
We spoke to current AACR President Lillian Siu about translational gaps, the difficulties of first-in-human trials and the things drug-discovery gets wrong about clinical deployment.
The first patient has been dosed in a phase 1 clinical trial of NVG222, NovalGen’s next-generation self-regulating T-cell engager for treating ROR1-positive blood cancers. The trial is delivered at our Centre for Drug Development and led by Chief Investigator Will Townsend at University College London Hospitals NHS Foundation Trust.
C-Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics for Ewing sarcoma, bone sarcoma, medulloblastoma and childhood acute myeloid leukaemia.
Our strategy shapes how we'll discover more about the mechanisms of how cancer develops and progresses to unlock new and better ways to prevent, detect and treat it.
Whether you’re an academic researcher seeking practical advice and inspiration or just want to hear about others' translation journeys, this podcast series has something for you.
We host scientific conferences, workshops, webinars and other events. Join us to hear about the latest science, present your research and network with our exceptional community.
Subscribe to our newsletters to hear about the latest news, funding opportunities, events and conferences and other research stories.
Explore our latest articles and podcasts for researchers, exploring issues in cancer science and how that science shapes our understanding of the disease.
